How to Store Research Peptides for Maximum Stability

Every degradation event that occurs between the moment a lyophilized peptide vial leaves the manufacturer and the moment it enters an assay is invisible, until it wrecks a result. A 2017 analysis of plasma peptide handling demonstrated that samples maintained at room temperature for as little as two hours showed degradation of labile peptides to a degree that would meaningfully distort pharmacokinetic data. 6 Reproducibility in peptide research is not primarily a statistical problem; it is a cold-chain and handling problem. This protocol translates the peer-reviewed stability literature into a set of concrete, laboratory-executable steps that any biochemist, clinical pharmacist, or lab manager can apply immediately.

The guidance here covers lyophilized (dry powder) peptides as received from a supplier, through reconstitution, aliquoting, and long-term frozen storage, to the moment of thaw immediately before use. Each step is anchored to published mechanistic evidence explaining why the step matters, because understanding the degradation pathway is the only durable protection against ad hoc shortcuts eroding it.

Why This Protocol Matters

The Biochemistry of Peptide Degradation

Peptides are not passive molecules in storage. Several distinct chemical reactions proceed spontaneously at measurable rates even well below ambient temperature, and each one produces degradation products that are chemically distinct from the parent compound, meaning they can generate false signals, consume reagent without producing the intended assay response, or silently alter the effective concentration of the stock solution.

Deamidation is the most ubiquitous degradation pathway and affects asparagine (Asn, N) residues preferentially. The mechanism proceeds through a cyclic succinimide intermediate: the backbone nitrogen attacks the side-chain carbonyl to form a five-membered ring, which then opens to yield either aspartate (Asp) or isoaspartate in roughly a 1:3 ratio. 5 Molecular dynamics simulations have established that the syn rotameric conformation of the Asn side chain dramatically lowers the activation energy for this reaction, 89.3 kJ·mol⁻¹ versus 111 kJ·mol⁻¹ for the anti conformation, explaining why Asn-Gly motifs, where the glycine backbone permits maximal flexibility, are 10-100× more vulnerable than Asn-Pro or Asn-Ile sequences. 5 Temperature acceleration of deamidation is substantial: a rise from 4 °C to 25 °C roughly doubles the observed rate for many sequences, and the difference between −20 °C and +4 °C is larger still.

Hydrolysis at aspartate represents a parallel but distinct threat. Asp-Pro peptide bonds are at least 100-fold more labile than other peptide bonds under dilute acid conditions, a figure confirmed across multiple structural studies. 1 This matters operationally because many reconstitution buffers and diluents are mildly acidic (pH 4-6), and the assumption that acidic conditions are "safer" for hydrolysis-prone peptides needs qualification for any sequence containing an Asp-Pro motif.

Oxidation targets methionine (Met), cysteine (Cys), tryptophan (Trp), tyrosine (Tyr), and histidine (His) residues in roughly that order of reactivity toward dissolved oxygen and reactive oxygen species (ROS). 7 Methionine oxidizes to methionine sulfoxide (MetO) through a two-electron transfer, a reaction that can be driven by dissolved oxygen alone in the absence of any photosensitizer. 2 Cysteine oxidation is complicated by thiol-disulfide exchange, which can proceed even during lyophilization, meaning the solid-state does not fully suppress covalent modifications in Cys-containing peptides. 8

Aggregation deserves separate treatment because it is a physical rather than chemical form of instability, yet its consequences for assay validity are equally severe. Freeze-thaw cycling has been documented to increase aggregate formation multifold per cycle, with the thaw rate appearing to be the dominant variable: slow thawing favors aggregation because it prolongs the time peptide molecules spend in the concentrated, partially frozen state where intermolecular contacts are most frequent. 9

Why Room Temperature Handling Is Inadequate

A 2017 study by Bredehöft and colleagues examining plasma peptide stability demonstrated that samples stored at room temperature for two hours showed measurable degradation products compared to samples processed immediately on ice, with the effect compounding at the four-hour mark. 6 This is not a corner case: any researcher who lets a reconstituted peptide stock sit on the bench while preparing an assay plate is effectively dosing their assay with a mixture of parent compound and degradation products. The proportion of degradation products scales with exposure time, temperature, and the specific vulnerability profile of the peptide sequence.

Materials and Equipment

Selecting the right consumables is not a trivial step. Container material, closure type, and desiccant quality each have documented effects on peptide recovery and stability. The table below lists the minimum equipment set for this protocol.

A Note on Container Material and Peptide Adsorption

Container selection deserves its own discussion because the interaction between a peptide and its storage vessel is sequence-dependent and consequential. A systematic study by Gröschl and colleagues tested borosilicate glass tubes, polypropylene tubes, and siliconised tubes for recovery of ten gastrointestinal peptides including GLP-1, PYY, ghrelin, and CCK-8S. 10 Borosilicate glass provided maximal recovery for nesfatin-1, PYY, leptin, GLP-1, and CRF, while polypropylene was superior for ghrelin and CCK-8S. Siliconisation decreased recovery for most peptides tested, contradicting the intuitive expectation that a more inert surface would perform better. 10 The practical implication is that for most research peptides, low-bind polypropylene microcentrifuge tubes represent the best general-purpose choice, with borosilicate glass reserved for peptides where published data support its use or where compatibility with organic solvent diluents (such as DMSO) is required.

For detailed guidance on selecting and verifying diluent sources, see our how to reconstitute peptides guide and the BAC water product review.

Step-by-Step Protocol

This protocol assumes the researcher is starting with a lyophilized peptide vial as received from a supplier, and covers the full workflow through long-term frozen aliquot storage.

Step 1, Verify the Certificate of Analysis Before Opening Anything

Before touching the vial, confirm the peptide identity, purity, and molecular weight against the certificate of analysis (CoA). A purity ≥95% by HPLC (reversed-phase) is the minimum acceptable standard for most research applications; mass spectrometry confirmation of the correct molecular weight eliminates the possibility of a sequence error or contamination. For guidance on reading a CoA, see our how to read a CoA guide and how to verify purity guide.

Why this step matters: If the vial arrives with a purity of 88%, no storage protocol can rescue the experiment. Documenting the incoming purity also creates a baseline against which future degradation can be measured.

Step 2, Equilibrate the Vial to Room Temperature Before Opening

Remove the vial from the freezer or refrigerator and allow it to equilibrate to room temperature while still sealed and wrapped in its original packaging. This typically takes 15-30 minutes. Do not begin this step until you are ready to proceed immediately with reconstitution or aliquoting.

Rationale: When a cold vial is opened in a humid laboratory environment, the cold surface acts as a condensation nucleus. Moisture condenses directly onto the peptide powder, initiating hydrolysis and oxidation reactions immediately. Equilibrating to room temperature before opening eliminates the condensation driving force. 3 This single step is violated in a majority of casual laboratory workflows and is one of the most consequential errors a researcher can make.

Failure mode: The vial appears slightly fogged or damp inside after opening, this indicates condensation occurred, likely because equilibration time was insufficient or the lab humidity was unusually high. Proceed with reconstitution immediately; do not attempt to re-dry an opened vial in a standard laboratory oven.

Step 3, Prepare the Reconstitution Diluent

Select the reconstitution diluent based on the peptide's physicochemical properties:

• Hydrophilic peptides (logP < 0): Begin with sterile water or bacteriostatic water (BAC water). BAC water, 0.9% benzyl alcohol in water for injection, extends the working life of a reconstituted solution through antimicrobial action and is appropriate for most peptide research applications. See our BAC water review for supplier evaluation criteria.
• Moderately hydrophobic peptides: Start with a small volume (10-20% of final volume) of glacial acetic acid (10% v/v) or dilute HCl to dissolve the powder, then bring to volume with sterile water or appropriate buffer.
• Highly hydrophobic peptides (logP > 2): Dissolve in anhydrous DMSO first, then dilute stepwise with aqueous buffer. Maintain the final DMSO concentration below 10% v/v for most biological assays. 11
• Cysteine-containing peptides: Use a degassed diluent (sparge with argon or nitrogen for 10 minutes) and consider adding a reducing agent such as TCEP (tris(2-carboxyethyl)phosphine) at 1 mM if the free thiol form is required for the research application.

pH verification: Always verify the pH of the reconstituted solution with a calibrated pH meter. The target pH should be documented in the peptide supplier's technical data sheet; if no recommendation is given, pH 5-7 is generally appropriate as a starting range. Note that Asp-Pro containing peptides are significantly more stable at pH 5 than at pH 7, while Asn-Gly containing peptides show less pH dependence for their deamidation rate. 1

Step 4, Calculate and Prepare Working Concentration

Determine the target stock concentration based on the downstream assay requirements. The working rule of thumb from Kapp and colleagues, applied across multiple proteomics applications, is to target 0.5-1 mg/mL for aqueous formulations intended for repeated freeze-thaw cycles. 11 Higher concentrations increase the risk of aggregation on freeze-thaw; lower concentrations increase the risk of adsorptive losses to container surfaces dominating over the actual peptide signal.

For reconstitution mathematics, see the three worked examples in the Worked Examples section of this protocol.

Step 5, Add Diluent Slowly; Do Not Vortex

Add the calculated volume of diluent to the peptide vial (do not transfer the powder) by directing the stream down the inner wall of the vial rather than directly onto the powder cake. Gently swirl for 20-30 seconds. If the powder does not dissolve fully within two minutes of gentle swirling, allow the vial to sit at room temperature for an additional five minutes before attempting sonication in a water bath at room temperature (maximum 30 seconds, low-power setting).

Rationale for no vortex: Vigorous mechanical agitation at an air-liquid interface dramatically accelerates aggregation by repeatedly exposing peptide molecules to a high-energy surface that promotes conformational unfolding. 4 This interface-driven aggregation is particularly relevant for amphipathic peptides and peptides with high β-sheet propensity. Even brief vortexing of aggregation-prone peptides can generate visible or sub-visible particulates that are irreversible.

Failure mode: The solution appears cloudy after dissolving. Possible causes include insufficient diluent volume (too high a concentration), wrong pH, or intrinsic aggregation tendency of the sequence. Do not proceed with a cloudy solution; see the Troubleshooting section.

Step 6, Blanket the Headspace With Inert Gas and Aliquot Immediately

Immediately after confirming complete dissolution and clarity of the solution, blanket the headspace of the vial with a brief pulse of research-grade argon or nitrogen gas before capping. Then divide the solution into single-use aliquots in pre-labelled, low-bind polypropylene microcentrifuge tubes sized to contain a single working-session volume. A 0.5 mL tube is appropriate for aliquots ≤200 µL; a 1.5 mL tube for aliquots up to 1 mL.

Volume per aliquot: Size aliquots to the amount needed for one experimental session. Each freeze-thaw cycle adds measurable aggregation risk; aliquots should be used in their entirety on the day of thawing. 9

Labelling: Apply cryogenic-rated marker or label tape to each tube with: peptide name, lot number, concentration (mg/mL and µM), diluent, date prepared, and initials. Standard pen or adhesive labels delaminate at −80 °C; cryogenic marker ink survives indefinitely.

Step 7, Freeze Aliquots Rapidly and Store at −80 °C

Place capped aliquot tubes in a pre-cooled cryogenic storage box and transfer to the −80 °C freezer without delay. Rapid freezing is preferable to slow freezing for solution-state peptide aliquots because it minimises the time spent in the partially frozen, cryo-concentrated state where aggregation nucleation is most likely. 9 A shallow-well aluminium cooling block pre-chilled to −20 °C can serve as a rapid intermediate if the walk to the ULT freezer is more than a few seconds.

Lyophilized powder (if not reconstituting immediately): Return the unopened vial to its original sealed packaging, add a fresh silica gel desiccant sachet, wrap the vial cap-body junction with Parafilm, and store at −20 °C in a non-frost-free freezer. Frost-free freezers cycle through defrost events that can transiently elevate the freezer temperature to −5 to 0 °C and spike humidity within the compartment, exactly the conditions that drive moisture-mediated degradation of lyophilized peptides. 3

Step 8, Thawing Aliquots for Use

On the day of use, remove a single aliquot tube from the −80 °C freezer and thaw it rapidly by holding in a gloved hand or by placing in a 25 °C water bath for no more than two minutes. Do not use a 37 °C incubator or heating block; temperature overshoot during thawing accelerates degradation far more than the extra seconds spent thawing at room temperature. Once thawed, briefly centrifuge (5 seconds at low speed) to collect any condensate from the inner cap surface, then use within the same working session. Discard any unused thawed aliquot at the end of the session.

Common Mistakes to Avoid

Opening a Cold Vial in a Humid Environment

Described in detail in Step 2 above, this is the single most common and consequential handling error. It is also the most invisible: the condensed moisture evaporates within seconds of the vial warming, leaving no visible evidence that it occurred. The biochemical consequence, a bolus of liquid water delivered directly to the lyophilized peptide powder, initiates hydrolysis and oxidation that persist through subsequent storage. The fix is absolute: always equilibrate to room temperature before opening.

Storing Reconstituted Peptides at −20 °C Rather Than −80 °C

Many laboratories store reconstituted peptide solutions at −20 °C because that freezer is more accessible. The stability literature is clear that this is substantially inferior for aqueous peptide solutions. At −20 °C, unfrozen micro-aqueous domains persist within the ice matrix, providing a medium in which enzymatic and chemical degradation can continue at reduced but non-negligible rates. 7 Lyophilized powder at −20 °C under desiccation is a different matter, that storage condition is appropriate because the removal of bulk water is the primary protective mechanism, and −20 °C further suppresses residual moisture-mediated reactions.

Using a Frost-Free Freezer

The auto-defrost cycle in a frost-free freezer exposes samples to temperature fluctuations and humidity events at regular intervals. For lyophilized peptides, this is particularly damaging because the residual moisture target below 3.0 wt%, necessary to suppress solid-state degradation, can be exceeded during defrost events. 3 Use a conventional compressor-type freezer without auto-defrost for all peptide storage.

Re-using Thawed Aliquots

Re-freezing and re-thawing reconstituted peptide solutions multiplies the aggregation burden exponentially. The relationship between freeze-thaw cycle number and aggregate content is not linear; research on biologic macromolecules has demonstrated that aggregate formation can increase multifold after the second and third cycle relative to the first. 9 The correct approach is to size aliquots so that each one is consumed in a single session.

Ignoring Sequence-Specific Vulnerability

Applying a generic storage protocol uniformly to all peptides is a systematic error. A peptide containing Met-Gly-Gly-Trp requires inert-gas blanketing and a light-protected storage box that a simple Ala-Ala-Ala-Ala-Gly peptide does not. Taking ten minutes to review the sequence for Cys, Met, Trp, Asp-Pro, and Asn-Gly motifs before designing the storage plan saves weeks of troubleshooting later.

Storing All Peptides in the Same Box Without Desiccant

A storage box shared between multiple researchers in a busy laboratory opens and closes dozens of times per week. Each opening event introduces ambient-humidity air into the box. Without active desiccant, the cumulative moisture load inside the box, even inside a −20 °C freezer, can exceed the tolerance of lyophilized peptides over weeks. Silica gel sachets should be considered a consumable and replaced monthly, or immediately when the indicator changes colour.

Advanced Considerations

Cysteine-Containing and Disulfide-Bonded Peptides

Peptides with free thiol groups or disulfide bonds require a storage sub-protocol that addresses both oxidative stability and disulfide bond fidelity. Thiol-disulfide exchange can proceed during lyophilization itself, a finding confirmed by Ricci and colleagues who demonstrated that factors that routinely affect thiol-disulfide equilibria in solution, temperature, pH, initial peptide concentration, buffer type, did not suppress these reactions in the solid state during freeze-drying. 8 This means that even a freshly manufactured lyophilized Cys-containing peptide may carry a mixture of oxidation states if the lyophilization was not performed under inert atmosphere.

Practical countermeasures include: (1) reconstituting in degassed, nitrogen-sparged sterile water; (2) adding TCEP at 0.5-5 mM as a non-volatile, air-stable reducing agent to maintain free thiols; (3) blanketing headspace with argon before each closure; (4) storing in borosilicate glass rather than polypropylene when the peptide will be in solution for more than 24 hours; and (5) verifying the thiol/disulfide ratio by Ellman's assay or LC-MS before critical experiments.

Oxidation-Prone Residues and Light Exposure

Visible light in the 400-800 nm range drives photooxidation of Trp, Tyr, and Met through ROS generation, and the rate is paradoxically concentration-dependent: higher protein/peptide concentrations have been associated with increased radical formation under equivalent light exposure. 12 The mechanism is thought to involve photosensitiser impurities whose absolute abundance increases with total peptide concentration. The practical consequence is that standard amber-coloured glass vials are a minimum protection for Trp or Tyr containing peptides; aluminium foil wrapping of the outer box adds a second barrier.

For long-term storage, lyophilized Trp-containing peptides should be stored in the dark at −20 °C or below, and the reconstituted solution should be protected from bench-top fluorescent lighting throughout all handling steps. This is operationally feasible by wrapping aliquot tubes in foil during centrifugation and keeping the storage box inside an opaque outer container.

Formulation Strategies for Extended Solution Stability

When a research protocol requires a peptide to remain in solution at 4 °C for several days (for example, for continuous infusion experiments or iterative bioassay use), excipient co-formulation can extend working stability. The most well-evidenced approaches from the stability literature are:

pH optimisation: The pH at which the peptide's net degradation rate is minimised (the pH of maximum stability, or pH-opt) varies by sequence but is frequently in the range pH 5.0-6.5 for peptides containing both Asp and Asn residues. A systematic study on pharmaceutical peptide formulation by Kinnunen and colleagues confirmed that 50 mM phosphate buffer at pH 7.4 supported stability for certain sequences, while acetate at pH 5.0 was superior for others, reinforcing the need for sequence-specific optimisation. 13

Polyol excipients: Sucrose, trehalose, mannitol, and raffinose function as hydroxyl radical scavengers through their ability to donate hydrogen atoms to ROS, simultaneously protecting against oxidation and acting as cryoprotectants. 7 Among these, trehalose and sucrose are most studied; mannitol has been shown to promote crystallisation in lyophilized cakes under high humidity, which can accelerate aggregate formation compared to amorphous-state excipients. 14

Co-solvent addition: Acetonitrile (ACN) at 5-30% with 0.1% formic acid is the formulation used in proteomics workflows to prevent adsorptive loss during storage and to suppress enzymatic degradation. 11 This formulation is not suitable for cell-based bioassays but is appropriate for mass spectrometry reference standards.

Air exclusion: Sparging the reconstitution buffer with argon or nitrogen for 10 minutes before use, and then blanketing each aliquot before capping, reduces dissolved oxygen content by >90% and directly suppresses Met and Cys oxidation kinetics. 7

Accelerated Stability Testing to Predict Shelf Life

For laboratories that generate or purchase large batches of a critical peptide and need to estimate shelf life under intended storage conditions, accelerated stability testing provides a practical framework. The approach uses degradation rate data collected at elevated temperatures (typically 25 °C, 40 °C, and 60 °C) with Arrhenius kinetics to back-calculate expected rates at −20 °C or −80 °C. 15 However, this methodology has documented limitations for solid-state peptides: deviations from Arrhenius predictions have been observed when the degradation pathway itself changes between temperature regimes (for example, deamidation dominated above 40 °C but oxidation dominated at 4 °C for one formulation studied by Dorion-Thibaudeau and colleagues). 15 For this reason, accelerated stability predictions should be validated against real-time stability data collected at the intended storage temperature whenever a large batch justifies the investment.

Troubleshooting

Interpreting HPLC Degradation Peaks

When a re-test HPLC trace shows new peaks not present in the original CoA, their position and molecular weight by LC-MS provide mechanistic information. Peaks eluting earlier than the parent compound (more hydrophilic) typically indicate deamidation (+0.984 Da on MS) or hydrolysis products. Peaks eluting later (more hydrophobic) may indicate dimerisation or disulfide-bonded species. A +16 Da shift confirms methionine or tryptophan oxidation; +32 Da indicates the sulfone (double oxidation of Met). 16 These assignments are not definitive without tandem MS fragmentation but serve as a rapid first-pass triage to identify the degradation pathway and select the appropriate corrective action.

After the Protocol, Documentation and Records

What to Record at Each Step

Regulatory-grade research documentation, essential for any publication or IND-supporting study, requires a log entry at every decision point. For peptide storage specifically, the minimum record should include:

• Peptide name, supplier, lot number, and incoming purity (transcribed from CoA)
• Date received and date opened
• Equilibration method and duration before opening
• Diluent composition, pH, and source (lot number for BAC water or other diluent)
• Final stock concentration (mg/mL and µM) with calculation shown
• Volume per aliquot, number of aliquots prepared
• Storage location (freezer ID, shelf, box position)
• Date and outcome of each thaw event (volume used, remaining aliquots)
• Any anomalies observed (cloudiness, off-colour, unexpected precipitation)

A simple template in the laboratory notebook or electronic lab notebook (ELN) reduces the time cost of this documentation to under two minutes per session while providing full traceability.

Stability Re-Testing Schedule

For peptides used over an extended period (>3 months for lyophilized; >1 month for reconstituted), incorporate periodic re-testing into the workflow. A simple RP-HPLC purity check against the original CoA baseline, performed at the beginning of any critical experimental series, takes 20 minutes and eliminates a significant source of inter-experiment variability. If the re-test purity has declined by more than 2% absolute from the CoA value, treat the affected aliquots as suspect and order fresh material before proceeding with experiments where peptide purity is a primary variable.

Worked Examples

Example 1, Reconstituting a 5 mg Lyophilized BPC-157 Vial to 1 mg/mL Stock

Given:

• Vial contents: 5 mg lyophilized BPC-157 (MW ≈ 1,419.5 g/mol)
• Target stock concentration: 1 mg/mL
• Intended diluent: bacteriostatic water (BAC water)
• Planned aliquot size: 500 µL (sufficient for one assay session)

Calculation:

Volume of diluent required = mass ÷ target concentration = 5 mg ÷ 1 mg/mL = 5.0 mL

Number of 500 µL aliquots = 5,000 µL ÷ 500 µL = 10 aliquots

Molar concentration of stock = (1 mg/mL ÷ 1,419.5 g/mol) × 1,000 mg/g × 1,000 mL/L = 704 µM

Procedure notes: Add 5.0 mL BAC water to the vial in 1 mL increments, swirling gently between additions. BPC-157 is a water-soluble peptide and should dissolve within 1-2 minutes at room temperature. Verify pH (target: 6.5-7.0). Divide into 10 × 500 µL aliquots in low-bind 1.5 mL polypropylene tubes. Label each tube with: BPC-157, lot number, 1 mg/mL / 704 µM, BAC water pH 6.8, preparation date. Transfer immediately to −80 °C. Each aliquot provides one working-session volume. Do not re-freeze thawed aliquots.

Shelf life expectation: Lyophilized BPC-157 stored at −20 °C under desiccation is stable for ≥12 months in most published stability estimates; reconstituted solution at −80 °C should be considered reliable for ≤3 months, with re-testing recommended at the 6-week mark for critical experiments.

Example 2, Preparing Low-Volume Aliquots of a Hydrophobic Peptide Using DMSO

Given:

• Peptide: hypothetical hydrophobic decapeptide, MW = 1,050 g/mol, 2 mg lyophilized
• Target: 10 mM stock in DMSO (for serial dilution into cell culture media)
• Planned aliquot size: 20 µL (single-use for one 96-well plate experiment)

Step 1, Dissolve in DMSO:

Volume of DMSO for 10 mM = (mass in mmol) × (1 mL / 1 mmol concentration)

Mass in mmol = 2 mg ÷ 1,050 mg/mmol = 1.905 × 10⁻³ mmol

Volume at 10 mM = 1.905 × 10⁻³ mmol ÷ 10 mmol/mL = 0.190 mL = 190 µL DMSO

Step 2, Aliquot:

Number of 20 µL aliquots = 190 µL ÷ 20 µL = 9 aliquots (with ~10 µL dead volume)

Step 3, Working dilution for assay:

For a final assay concentration of 10 µM in 200 µL assay volume with ≤0.1% DMSO:

Volume of 10 mM stock per well = (10 µM × 200 µL) ÷ 10,000 µM = 0.2 µL

DMSO contribution = 0.2 µL ÷ 200 µL = 0.1%, exactly at the limit. This is acceptable for most cell-based assays. 11

Procedure notes: Use only anhydrous DMSO ≥99.9% to minimize water content. Dissolve by gentle pipette mixing; avoid vortexing. Confirm complete dissolution visually. Blanket each 20 µL aliquot tube with argon before capping. Store at −20 °C (DMSO solutions do not freeze solidly at −20 °C but remain highly viscous, with effectively suppressed reaction kinetics). Thaw by hand warming; the solution becomes fluid immediately. Use entire aliquot per experiment session; discard remainder.

Example 3, Estimating Remaining Active Peptide After a Known Storage Excursion

Scenario: A 1 mg/mL reconstituted peptide solution containing a Met residue was accidentally left at +4 °C for 72 hours instead of being stored at −80 °C. How much oxidation is expected, and is the batch usable?

Published reference data: For Met-containing peptides in aqueous solution at pH 7, oxidation to MetO has been estimated at approximately 1-5% per day at 4 °C in air-saturated solution, depending on dissolved oxygen and the presence of metal ion impurities. 16 A conservative estimate of 3%/day gives:

Estimated MetO formation after 3 days = 3% × 3 = ~9% of total peptide

Remaining intact parent peptide ≈ ~91%, which is above the 95% purity threshold typically required for research use.

Decision framework:

• Run RP-HPLC on the affected batch and identify the MetO peak (expected to elute slightly earlier than parent compound on a C18 column).
• If measured MetO + other impurities < 5%: batch is usable with documentation of the excursion in the laboratory notebook.
• If measured impurities 5-10%: usable only for non-critical screening; not suitable as a primary reference standard.
• If measured impurities > 10%: discard and order fresh material.

Preventive measure: Future aliquots of this peptide should be prepared with degassed BAC water, headspace argon blanketing, and stored in amber-coloured tubes at −80 °C. See the sequence-risk checklist in the Advanced Considerations section for a pre-storage vulnerability assessment.